Trial · NCT05583526
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
NCT05583526, Phase 3, Completed, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo. Trials, record NCT05583526. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05583526
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
- NCT number
- NCT05583526
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 607 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
- Interventions
- Ritlecitinib, Placebo
- First posted
- 2022-10-17
- Last updated
- 2026-02-27
Source ClinicalTrials.gov
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and T-VASI50 at Week 52 | Week 52 | Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) and T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
| Primary | Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 | Week 52 | Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) |
| Primary | Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs), leading to discontinuation, and clinically significant laboratory abnormalities | Baseline through Week 52 | Safety and tolerability of ritlecitinib in participants with nonsegmental vitiligo |
| Secondary | US-Only: Response based on F-VASI75 at 24 and 36 weeks | Weeks 24 and 36 | Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline |
| Secondary | US-Only: Response based on T-VASI50 at 24 and 36 weeks | Weeks 24 and 36 | Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
| Secondary | US-Only: Response based on T-VASI75 at 52 weeks | Week 52 | Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline) |
| Secondary | US-Only: Percentage change from baseline (% CFB) in F-VASI at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Median % CFB in F-VASI in participants treated with ritlecitinib 50 mg QD versus placebo |
| Secondary | US-Only: Percentage change from baseline (% CFB) in T-VASI at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Median % CFB in T-VASI in participants treated with ritlecitinib 50 mg QD versus placebo |
| Secondary | US-Only: Patient Global Impression of Severity-Face (PGIS-F) | Week 52 | Proportion of responders based on PGIS-F at 52 weeks |
| Secondary | US-Only: Patient Global Impression of Severity-Overall Vitiligo (PGIS-V) | Week 52 | Proportion of responders based on PGIS-V at 52 weeks |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42171987 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05583526
GET https://conductscience.org/api/trials/v1/NCT05583526/registered?page=2